Diaceutics PLC (LON:DXRX - Get Free Report)'s stock price shot up 2.3% during mid-day trading on Thursday . The stock traded as high as GBX 134 ($1.82) and last traded at GBX 132 ($1.79). 83,595 shares changed hands during trading, a decline of 33% from the average session volume of 124,969 shares. The stock had previously closed at GBX 129 ($1.75).
Diaceutics Trading Up 2.3%
The stock has a market cap of £111.40 million, a price-to-earnings ratio of -39.15 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average of GBX 122.97 and a 200-day moving average of GBX 128.46.
Diaceutics (LON:DXRX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported GBX (2.02) (($0.03)) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. As a group, research analysts forecast that Diaceutics PLC will post 1.0107919 earnings per share for the current year.
Insider Buying and Selling at Diaceutics
In related news, insider Peter Keeling sold 500,000 shares of Diaceutics stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of GBX 126 ($1.71), for a total transaction of £630,000 ($855,513.31). Corporate insiders own 34.30% of the company's stock.
About Diaceutics
(
Get Free Report)
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diaceutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.
While Diaceutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
